

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE
Review Proposal Project

**Review of NICE Technology Appraisal Guidance TA431: mepolizumab for treating
severe eosinophilic asthma ID3750**
Matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company/sponsor</u></p> <ul style="list-style-type: none"> • GlaxoSmithKline (mepolizumab) <p><u>Patient groups</u></p> <ul style="list-style-type: none"> • Action Against Allergy • Allergy UK • Asthma UK • British Lung Foundation • European Federation of Allergy and Airway Diseases Patients Association (EFA) • Muslim Council of Britain • NARA – The Breathing Charity • South Asian Health Foundation • Specialised Healthcare Alliance • The Anaphylaxis Campaign <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association of Respiratory Nurse Specialists • British Geriatrics Society • British Society for Allergy & Clinical Immunology • British Thoracic Society • ILD-IN: Interstitial Lung Diseases Interdisciplinary Network • National Heart and Lung Institute • Primary Care Respiratory Society UK • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine Specialists • UK Clinical Pharmacy Association 	<p><u>General commentators</u></p> <ul style="list-style-type: none"> • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare Products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Confederation • Scottish Medicines Consortium • Welsh Health Specialised Services Committee <p><u>Comparators</u></p> <ul style="list-style-type: none"> • Astra Zeneca • Teva Pharmaceuticals <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Asthma, Allergy and Inflammation Research Trust • British Association for Lung Research • Cochrane Airways Group • Genomics England • MRC Clinical Trials Unit • National Institute for Health Research <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • Public Health England

NICE Technology Appraisal ID3750 mepolizumab for treating severe eosinophilic asthma (review of technology appraisal guidance 431)

Issue date: February 2020

© National Institute for Health and Care Excellence 2020

All rights reserved. [Subject to Notice of rights.](#)

Page 1 of 3

<p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health and Social Care • NHS Bedfordshire CCG • NHS Calderdale CCG • NHS England • Welsh Government 	<ul style="list-style-type: none"> • Public Health Wales
--	---

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to prepare a submission dossier, can respond to consultations, nominate clinical experts and has the right to appeal against the Final Appraisal Document (FAD).

All non- company consultees are invited to prepare a submission dossier respond to consultations on the draft scope, the Assessment Report and the Appraisal Consultation Document. They can nominate clinical or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

Commentators

Organisations that engage in the appraisal process but are not asked to prepare a submission dossier. Commentators are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, and the British National Formulary).

All non-company organisations can nominate clinical or patient experts to present their personal views to the Appraisal Committee.